Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Assets (2016 - 2025)

Aptevo Therapeutics (APVO) has disclosed Assets for 11 consecutive years, with $27.0 million as the latest value for Q3 2025.

  • Quarterly Assets rose 78.24% to $27.0 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $27.0 million through Sep 2025, up 78.24% year-over-year, with the annual reading at $15.6 million for FY2024, 37.24% down from the prior year.
  • Assets hit $27.0 million in Q3 2025 for Aptevo Therapeutics, up from $15.6 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $71.5 million in Q2 2021 to a low of $8.3 million in Q1 2025.
  • Historically, Assets has averaged $33.7 million across 5 years, with a median of $28.9 million in 2023.
  • Biggest five-year swings in Assets: skyrocketed 286.16% in 2021 and later plummeted 52.68% in 2025.
  • Year by year, Assets stood at $56.6 million in 2021, then tumbled by 39.55% to $34.2 million in 2022, then decreased by 27.39% to $24.8 million in 2023, then crashed by 37.24% to $15.6 million in 2024, then surged by 73.15% to $27.0 million in 2025.
  • Business Quant data shows Assets for APVO at $27.0 million in Q3 2025, $15.6 million in Q2 2025, and $8.3 million in Q1 2025.